两种重组二聚体RBD新冠疫苗候选物的随机双盲I期临床试验:安全性、反应原性与免疫原性
在古巴哈瓦那国家毒理学中心开展的随机双盲I期试验中,60名19-59岁志愿者随机分为三组,分别接种FINLAY-FR-1(50微克d-RBD+脑膜炎奈瑟菌外膜囊泡)、FINLAY-FR-1A-50(50微克d-RBD三剂)或FINLAY-FR-1A-25(25微克d-RBD三剂)。疫苗候选物安全且具免疫原性,可诱导针对SARS-CoV-2的活病毒中和抗体;以外膜囊泡为佐剂时获得最高值。
要点
- 大多数不良事件为轻度(63.5%)、征集性(58.8%)和局部(61.8%),未发现严重不良事件。
- 第三剂后抗RBD血清转化率:FINLAY-FR-1组100%、FINLAY-FR-1A-50组94.4%、FINLAY-FR-1A-25组90%。
- FINLAY-FR-1组第三剂后中和抗体几何均滴度显著高于其他制剂和新冠恢复期血清面板。
核心结论
- 疫苗候选物安全且具免疫原性,可诱导针对SARS-CoV-2的活病毒中和抗体。
- 使用外膜囊泡作为佐剂时获得最高值。
研究设计与样本
- 在哈瓦那国家毒理学中心开展的随机双盲I期临床试验。
- 60名19-59岁古巴志愿者随机分为三组(每组20人):FINLAY-FR-1(50微克d-RBD加脑膜炎奈瑟菌外膜囊泡)、FINLAY-FR-1A-50(50微克d-RBD三剂)、FINLAY-FR-1A-25(25微克d-RBD三剂)。
- FINLAY-FR-1组随机分为接受同源方案(同种疫苗候选物第三剂)或异源方案(FINLAY-FR-1A-50第三剂)。
- 主要结局为安全性和反应原性,次要结局为疫苗免疫原性。
主要发现
- 大多数不良事件为轻度(63.5%)、征集性(58.8%)和局部(61.8%);69.4%与疫苗接种有因果关系;未发现严重不良事件。
- FINLAY-FR-1组报告不良事件的受试者多于其他两组。
- 第三剂后抗RBD血清转化率:FINLAY-FR-1组100%、FINLAY-FR-1A-50组94.4%、FINLAY-FR-1A-25组90%。
- 所有制剂第二剂后RBD:hACE2相互作用的体外抑制均增加。
- FINLAY-FR-1组第三剂后中和抗体几何均滴度较其他制剂和新冠恢复期血清面板显著升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the target for many COVID-19 vaccines. Here we report results for phase I clinical trial of two COVID-19 vaccine candidates based on recombinant dimeric RBD (d-RBD). METHODS: We performed a randomized, double-blind, phase I clinical trial in the National Centre of Toxicology in Havana. Sixty Cuban volunteers aged 19-59 years were randomized into three groups (20 subjects each): 1) FINLAY-FR-1 (50 µg d-RBD plus outer membrane vesicles from N. meningitidis); 2) FINLAY-FR-1A-50 (50 µg d-RBD, three doses); 3) FINLAY-FR-1A-25 (25 µg d-RDB, three doses). The FINLAY-FR-1 group was randomly divided to receive a third dose of the same vaccine candidate (homologous schedule) or FINLAY-FR-1A-50 (heterologous schedule). The primary outcomes were safety and reactogenicity. The secondary outcome was vaccine immunogenicity. Humoral response at baseline and following each vaccination was evaluated using live-virus neutralization test, anti-RBD IgG ELISA and in-vitro neutralization test of RBD:hACE2 interaction. RESULTS: Most adverse events were of mild intensity (63.5%), solicited (58.8%), and local (61.8%); 69.4% with causal association with vaccination. Serious adverse events were not found. The FINLAY-FR-1 group reported more subjects with adverse events than the other two groups. After the third dose, anti-RBD seroconversion was 100%, 94.4% and 90% for the FINLAY-FR-1, FINLAY-FR-1A-50 and FINLAY-FR-1A-25 respectively. The in-vitro inhibition of RBD:hACE2 interaction increased after the second dose in all formulations. The geometric mean neutralizing titres after the third dose rose significantly in the group vaccinated with FINLAY-FR-1 with respect to the other formulations and the COVID-19 Convalescent Serum Panel. No differences were found between FINLAY-FR-1 homologous or heterologous schedules. CONCLUSIONS: Vaccine candidates were safe and immunogenic, and induced live-virus neutralizing antibodies against SARS-CoV-2. The highest values were obtained when outer membrane vesicles were used as adjuvant. TRIAL REGISTRY: https://rpcec.sld.cu/en/trials/RPCEC00000338-En.
引用
- Pérez-Rodríguez S, de la Caridad Rodríguez-González M, Ochoa-Azze R, et al. A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity. Vaccine. 2022. PMID: 35164986. doi:10.1016/j.vaccine.2022.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。